צמיחת רווחי EPS רבעונית Seelos Therapeutics (SEEL)

The profit potential of Seelos Therapeutics (SEEL) is embedded in the therapy of rare psychiatric pathologies and suicidal states. Quarterly EPS variability demonstrates the market's reaction to these expectations, where 0.00 represents the current metric. The business foundation relies on intranasal ketamine patents, while the primary growth driver is the preparation of Phase 2 trial results for the drug SLS-002.
פילוחי נתונים אנליטיים מרוכזים עבור Seelos Therapeutics (SEEL)

Seelos Therapeutics (SEEL) progress in developing the SLS-002 drug and potential partnerships with biotech firms directly impact the issuer's market capitalization. By analyzing the quarterly EPS evolution metric on the GURU.Markets platform, an investor can track net income per share dynamics, which allows for an assessment of the business's financial resilience to macroeconomic shocks and minimizes the risk of deep drawdowns during a trend reversal.